QuickLinks -- Click here to rapidly navigate through this document
Exhibit 99.2
BRISTOL-MYERS SQUIBB COMPANY
SALES
FOR THE PERIOD ENDED SEPTEMBER 30, 2003
($ in millions)
| 2003 | 2002 | Percentage Change | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quarter-to-Date | Amount | % of Total | Amount | % of Total | Including Foreign Exchange | Excluding Foreign Exchange | |||||||||||
Pharmaceuticals | $ | 4,389 | 82.2 | % | $ | 3,687 | 81.3 | % | 19 | % | 15 | % | |||||
US Pharmaceuticals | 2,714 | 50.9 | % | 2,261 | 49.8 | % | 20 | % | 20 | % | |||||||
Primary Care | 1,774 | 33.3 | % | 1,344 | 29.6 | % | 32 | % | 32 | % | |||||||
Oncology/Virology/OTN | 940 | 17.6 | % | 917 | 20.2 | % | 3 | % | 3 | % | |||||||
Latin America/Canada | 251 | 4.7 | % | 219 | 4.8 | % | 15 | % | 14 | % | |||||||
Europe and Middle East Medicines | 1,102 | 20.6 | % | 908 | 20.0 | % | 21 | % | 5 | % | |||||||
Asia/Pacific Medicines | 262 | 4.9 | % | 240 | 5.3 | % | 9 | % | 5 | % | |||||||
Nutritionals | 514 | 9.7 | % | 445 | 9.8 | % | 16 | % | 16 | % | |||||||
Other Healthcare | 434 | 8.1 | % | 405 | 8.9 | % | 7 | % | 3 | % | |||||||
ConvaTec | 221 | 4.1 | % | 187 | 4.1 | % | 18 | % | 10 | % | |||||||
Medical Imaging | 130 | 2.4 | % | 118 | 2.6 | % | 10 | % | 8 | % | |||||||
Consumer Medicines | 83 | 1.6 | % | 100 | 2.2 | % | -17 | % | -17 | % | |||||||
Total Company | $ | 5,337 | 100.0 | % | $ | 4,537 | 100.0 | % | 18 | % | 14 | % | |||||
| 2003 | 2002 | Percentage Change | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Year-to-Date | Amount | % of Total | Amount | % of Total | Including Foreign Exchange | Excluding Foreign Exchange | |||||||||||
Pharmaceuticals | $ | 12,487 | 82.7 | % | $ | 10,809 | 81.1 | % | 16 | % | 12 | % | |||||
US Pharmaceuticals | 7,694 | 51.0 | % | 6,701 | 50.3 | % | 15 | % | 15 | % | |||||||
Primary Care | 4,811 | 31.9 | % | 4,099 | 30.8 | % | 17 | % | 17 | % | |||||||
Oncology/Virology/OTN | 2,883 | 19.1 | % | 2,602 | 19.5 | % | 11 | % | 11 | % | |||||||
Latin America/Canada | 715 | 4.7 | % | 644 | 4.8 | % | 11 | % | 19 | % | |||||||
Europe and Middle East Medicines | 3,159 | 20.9 | % | 2,614 | 19.6 | % | 21 | % | 4 | % | |||||||
Asia/Pacific Medicines | 743 | 4.9 | % | 659 | 4.9 | % | 13 | % | 6 | % | |||||||
Nutritionals | 1,383 | 9.2 | % | 1,365 | 10.3 | % | 1 | % | 2 | % | |||||||
Other Healthcare | 1,230 | 8.1 | % | 1,151 | 8.6 | % | 7 | % | 2 | % | |||||||
ConvaTec | 602 | 4.0 | % | 539 | 4.0 | % | 12 | % | 3 | % | |||||||
Medical Imaging | 378 | 2.5 | % | 340 | 2.6 | % | 11 | % | 10 | % | |||||||
Consumer Medicines | 250 | 1.6 | % | 272 | 2.0 | % | -8 | % | -10 | % | |||||||
Total Company | $ | 15,100 | 100.0 | % | $ | 13,325 | 100.0 | % | 13 | % | 9 | % | |||||
1
BRISTOL-MYERS SQUIBB COMPANY
SEGMENT SALES AND COMPOSITION OF CHANGE IN SALES FOR CONTINUING OPERATIONS
FOR THE PERIOD ENDED SEPTEMBER 30, 2003
(DOLLARS IN MILLIONS)
QUARTER-TO-DATE | Pharmaceuticals | Nutritionals | Convatec | Medical Imaging | Consumer Medicines | Company | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Price Increases(Decreases) | 1 | % | 4 | % | 2 | % | 2 | % | — | 1 | % | |||||||||
Foreign Exchange | 4 | % | — | 8 | % | 2 | % | — | 4 | % | ||||||||||
Volume | 14 | % | 12 | % | 8 | % | 6 | % | -17 | % | 13 | % | ||||||||
Total Change | 19 | % | 16 | % | 18 | % | 10 | % | -17 | % | 18 | % | ||||||||
Total 2003 Period to Date Sales | $ | 4,389 | $ | 514 | $ | 221 | $ | 130 | $ | 83 | $ | 5,337 | ||||||||
Total 2002 Period to Date Sales | $ | 3,687 | $ | 445 | $ | 187 | $ | 118 | $ | 100 | $ | 4,537 |
YEAR-TO-DATE | Pharmaceuticals | Nutritionals | Convatec | Medical Imaging | Consumer Medicines | Company | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Price Increases(Decreases) | 2 | % | -1 | % | 1 | % | 5 | % | — | 2 | % | |||||||||
Foreign Exchange | 4 | % | -1 | % | 9 | % | 1 | % | 2 | % | 4 | % | ||||||||
Volume | 10 | % | 3 | % | 2 | % | 5 | % | -10 | % | 7 | % | ||||||||
Total Change | 16 | % | 1 | % | 12 | % | 11 | % | -8 | % | 13 | % | ||||||||
Total 2003 Period to Date Sales | $ | 12,487 | $ | 1,383 | $ | 602 | $ | 378 | $ | 250 | $ | 15,100 | ||||||||
Total 2002 Period to Date Sales | $ | 10,809 | $ | 1,365 | $ | 539 | $ | 340 | $ | 272 | $ | 13,325 |
2
BRISTOL-MYERS SQUIBB COMPANY
2003 THIRD QUARTER REVIEW
($ in Million)
Corporate Overview—Continuing Operations
Revenues: | 2003 | % of Total | 2002 | % of Total | % Var. | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceuticals | $ | 4,389 | 82.2 | % | $ | 3,687 | 81.3 | % | 19 | % | ||||
Nutritionals | 514 | 9.7 | % | 445 | 9.8 | % | 16 | % | ||||||
Other Healtcare | 434 | 8.1 | % | 405 | 8.9 | % | 7 | % | ||||||
ConvaTec | 221 | 4.1 | % | 187 | 4.1 | % | 18 | % | ||||||
Medical Imaging | 130 | 2.4 | % | 118 | 2.6 | % | 10 | % | ||||||
Consumer Medicines | 83 | 1.6 | % | 100 | 2.2 | % | -17 | % | ||||||
5,337 | 100.0 | % | 4,537 | 100.0 | % | 18 | % | |||||||
Expenses: | | % of Sales | | % of Sales | % Var. | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
COGS | 1,908 | 35.8 | % | 1,654 | 36.5 | % | 15 | % | |||||
SG&A | 1,118 | 20.9 | % | 971 | 21.3 | % | 15 | % | |||||
Adv. & Promo. | 375 | 7.0 | % | 302 | 6.6 | % | 24 | % | |||||
R&D | 568 | 10.7 | % | 535 | 11.8 | % | 6 | % | |||||
Acquired in-process research & development | — | — | 7 | 0.2 | % | -100 | % | ||||||
Provision for restructuring | 13 | 0.2 | % | (11 | ) | -0.2 | % | * | |||||
Litigation settlement | (4 | ) | -0.1 | % | 569 | 12.5 | % | -101 | % | ||||
Asset impairment charge for ImClone | — | — | 379 | 8.4 | % | -100 | % | ||||||
Other (Inc)/Exp | 67 | 1.3 | % | 16 | 0.4 | % | * | ||||||
4,045 | 75.8 | % | 4,422 | 97.5 | % | -9 | % | ||||||
Earnings from Continuing Operations Before Minority Interest and IncomeTaxes | 1,292 | 24.2 | % | 115 | 2.5 | % | * | ||||||
Provision for income taxes | 317 | (252 | ) | ||||||||||
Minority interest, net of taxes | 91 | 28 | |||||||||||
Earnings from Continuing Operations | $ | 884 | 16.6 | % | $ | 339 | 7.5 | % | 161 | % | |||
Earnings Per Share—Basic | $ | 0.46 | $ | 0.18 | 156 | % | |||||||
Average Shares—Basic | 1,937 | 1,936 | |||||||||||
Earnings Per Share—Diluted | $ | 0.45 | $ | 0.17 | 165 | % | |||||||
Average Shares—Diluted | 1,944 | 1,941 |
- *
- in excess of 200%
Selected Products | Worldwide Sales $ in Millions | % Var. | Change in U.S. Rx Demand 3Q03 vs. 3Q02 | |||||
---|---|---|---|---|---|---|---|---|
Pravachol/Pravigard Pac | $ | 787 | 16 | % | 4 | % | ||
Plavix | 694 | 57 | % | 28 | % | |||
Enfamil | 209 | 7 | % | N/A | ||||
Avapro/Avalide | 182 | 48 | % | 14 | % | |||
Ostomy | 133 | 17 | % | N/A | ||||
Glucophage XR | 103 | 14 | % | -1 | % | |||
Sustiva | 95 | -14 | % | 18 | % | |||
Glucovance | 91 | 44 | % | 1 | % | |||
Wound Care | 85 | 21 | % | N/A | ||||
Coumadin | 67 | -19 | % | -14 | % | |||
Zerit | 65 | -46 | % | -25 | % | |||
Videx/Videx EC | 57 | -15 | % | 4 | % |
3
Other (Income)/Expense
| 2003 | 2002 | |||
---|---|---|---|---|---|
Interest Expense | 106 | 104 | |||
Interest Income | (73 | ) | (39 | ) | |
Foreign Exchange | 9 | (7 | ) | ||
Other—net | 25 | (42 | ) | ||
67 | 16 |
4
BRISTOL-MYERS SQUIBB COMPANY
2003 NINE MONTH REVIEW
($ in Millions)
Corporate Overview—Continuing Operations
Revenues: | 2003 | % of Total | 2002 | % of Total | % Var. | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceuticals | $ | 12,487 | 82.7 | % | $ | 10,809 | 81.1 | % | 16 | % | ||||
Nutritionals | 1,383 | 9.2 | % | 1,365 | 10.3 | % | 1 | % | ||||||
Other Healtcare | 1,230 | 8.1 | % | 1,151 | 8.6 | % | 7 | % | ||||||
ConvaTec | 602 | 4.0 | % | 539 | 4.0 | % | 12 | % | ||||||
Medical Imaging | 378 | 2.5 | % | 340 | 2.6 | % | 11 | % | ||||||
Consumer Medicines | 250 | 1.6 | % | 272 | 2.0 | % | -8 | % | ||||||
15,100 | 100.0 | % | 13,325 | 100.0 | % | 13 | % | |||||||
Expenses: | | % of Sales | | % of Sales | % Var. | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
COGS | 5,389 | 35.7 | % | 4,622 | 34.7 | % | 17 | % | |||||
SG&A | 3,208 | 21.1 | % | 2,820 | 21.2 | % | 14 | % | |||||
Adv. & Promo. | 1,157 | 7.7 | % | 906 | 6.8 | % | 28 | % | |||||
R&D | 1,574 | 10.4 | % | 1,564 | 11.7 | % | 1 | % | |||||
Acquired in-process research & development | — | — | 167 | 1.2 | % | -100 | % | ||||||
Gain on sale of businesses | — | — | (30 | ) | -0.2 | % | -100 | % | |||||
Provision for restructuring | 8 | 0.1 | % | (10 | ) | — | -180 | % | |||||
Litigation settlement | (66 | ) | -0.4 | % | 659 | 4.9 | % | -110 | % | ||||
Asset impairment charge for ImClone | — | — | 379 | 2.8 | % | -100 | % | ||||||
Other (Inc)/Exp, net | 298 | 2.0 | % | 181 | 1.4 | % | 65 | % | |||||
11,568 | 76.6 | % | 11,258 | 84.5 | % | 3 | % | ||||||
Earnings from Continuing Operations Before Minority Interest and Income Taxes | 3,532 | 23.4 | % | 2,067 | 15.5 | % | 71 | % | |||||
Provision for income taxes | 859 | 290 | |||||||||||
Minority interest, net of taxes | 150 | 117 | |||||||||||
Earnings from Continuing Operations | $ | 2,523 | 16.7 | % | $ | 1,660 | 12.5 | % | 52 | % | |||
Earnings Per Share—Basic | $ | 1.30 | $ | 0.86 | 51 | % | |||||||
Average Shares—Basic | 1,936 | 1,936 | |||||||||||
Earnings Per Share—Diluted | $ | 1.30 | $ | 0.85 | 53 | % | |||||||
Average Shares—Diluted | 1,942 | 1,943 |
- *
- in excess of 200%
5
Selected Products | Worldwide Sales $ in Millions | % Var. | Change in U.S. Rx Demand YTD 03 vs. YTD 02 | |||||
---|---|---|---|---|---|---|---|---|
Pravachol/Pravigard Pac | $ | 2,098 | 26 | % | 2 | % | ||
Plavix | 1,659 | 25 | % | 29 | % | |||
Avapro/Avalide | 527 | 28 | % | 14 | % | |||
Enfamil | 520 | -9 | % | N/A | ||||
Sustiva | 405 | 16 | % | 19 | % | |||
Ostomy | 369 | 11 | % | N/A | ||||
Glucovance | 315 | 84 | % | 5 | % | |||
Glucophage XR | 306 | 23 | % | 2 | % | |||
Zerit | 278 | -19 | % | -23 | % | |||
Coumadin | 249 | 5 | % | -14 | % | |||
Wound Care | 225 | 13 | % | N/A | ||||
Videx/Videx EC | 199 | 1 | % | 3 | % |
Other (Income)/Expense
| 2003 | 2002 | |||
---|---|---|---|---|---|
Interest Expense | 350 | 304 | |||
Interest Income | (190 | ) | (80 | ) | |
Foreign Exchange | 13 | 4 | |||
Other—net | 125 | (47 | ) | ||
298 | 181 |
6
BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE SALES BY PRODUCT
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2003
($ in millions)
| WORLDWIDE | INTERNATIONAL * | DOMESTIC * | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2003 | 2002 | % growth | 2003 | 2002 | % growth | 2003 | 2002 | % growth | ||||||||||||||||||
Total Company | $ | 5,337 | $ | 4,537 | 18 | % | $ | 2,038 | $ | 1,699 | 20 | % | $ | 3,299 | $ | 2,838 | 16 | % | |||||||||
PHARMACEUTICALS | 4,389 | 3,687 | 19 | % | 1,638 | 1,399 | 17 | % | 2,751 | 2,288 | 20 | % | |||||||||||||||
Cardiovasculars | 1,936 | 1,531 | 26 | % | 656 | 519 | 26 | % | 1,280 | 1,012 | 26 | % | |||||||||||||||
Pravachol/Pravigard Pac | 787 | 677 | 16 | % | 328 | 254 | 29 | % | 459 | 423 | 9 | % | |||||||||||||||
Plavix | 694 | 442 | 57 | % | 104 | 60 | 73 | % | 590 | 382 | 54 | % | |||||||||||||||
Avapro/ Avalide | 182 | 123 | 48 | % | 73 | 55 | 33 | % | 109 | 68 | 60 | % | |||||||||||||||
Monopril | 120 | 118 | 2 | % | 61 | 58 | 5 | % | 59 | 60 | -2 | % | |||||||||||||||
Coumadin | 67 | 83 | -19 | % | 7 | 6 | 17 | % | 60 | 77 | -22 | % | |||||||||||||||
Capoten/Captopril | 49 | 50 | -2 | % | 49 | 50 | -2 | % | — | — | — | ||||||||||||||||
Anti-Cancer | 1,121 | 1,003 | 12 | % | 309 | 262 | 18 | % | 812 | 741 | 10 | % | |||||||||||||||
Oncology Therapeutics Network | 574 | 495 | 16 | % | — | — | — | 574 | 495 | 16 | % | ||||||||||||||||
Paraplatin | 245 | 243 | 1 | % | 34 | 32 | 6 | % | 211 | 211 | — | ||||||||||||||||
TAXOL | 238 | 195 | 22 | % | 229 | 187 | 22 | % | 9 | 8 | 13 | % | |||||||||||||||
Anti-Infectives | 531 | 581 | - -9 | % | 355 | 335 | 6 | % | 176 | 246 | - -28 | % | |||||||||||||||
Sustiva | 95 | 110 | -14 | % | 52 | 40 | 30 | % | 43 | 70 | -39 | % | |||||||||||||||
Zerit | 65 | 120 | -46 | % | 41 | 50 | -18 | % | 24 | 70 | -66 | % | |||||||||||||||
Cefzil | 38 | 51 | -25 | % | 19 | 16 | 19 | % | 19 | 35 | -46 | % | |||||||||||||||
Videx/ Videx EC | 57 | 67 | -15 | % | 40 | 35 | 14 | % | 17 | 32 | -47 | % | |||||||||||||||
Tequin | 45 | 40 | 13 | % | 11 | 6 | 83 | % | 34 | 34 | — | ||||||||||||||||
Maxipime | 46 | 41 | 12 | % | 46 | 41 | 12 | % | — | — | — | ||||||||||||||||
Reyataz | 39 | — | — | 2 | — | — | 37 | — | — | ||||||||||||||||||
Central Nervous System | 69 | 89 | - -22 | % | 40 | 42 | - -5 | % | 29 | 47 | - -38 | % | |||||||||||||||
Serzone | 32 | 48 | -33 | % | 1 | 4 | -75 | % | 31 | 44 | -30 | % | |||||||||||||||
Sinemet | 20 | 29 | -31 | % | 21 | 20 | 5 | % | (1 | ) | 9 | -111 | % | ||||||||||||||
BuSpar | — | 10 | -100 | % | 7 | 7 | — | (7 | ) | 3 | *** | ||||||||||||||||
Other Pharmaceuticals | |||||||||||||||||||||||||||
Glucophage Franchise | 236 | 190 | 24 | % | 4 | 4 | — | 232 | 186 | 25 | % | ||||||||||||||||
Glucophage XR | 103 | 90 | 14 | % | — | — | — | 103 | 90 | 14 | % | ||||||||||||||||
Glucovance | 91 | 63 | 44 | % | — | 1 | -100 | % | 91 | 62 | 47 | % | |||||||||||||||
Glucophage | 36 | 37 | -3 | % | 3 | 3 | — | 33 | 34 | -3 | % | ||||||||||||||||
Metaglip | 6 | — | — | 1 | — | — | 5 | — | — | ||||||||||||||||||
Abilify** | 101 | — | — | 1 | — | — | 100 | — | — | ||||||||||||||||||
NUTRITIONALS | 514 | 445 | 16 | % | 236 | 215 | 10 | % | 278 | 230 | 21 | % | |||||||||||||||
Infant Formulas | 333 | 290 | 15 | % | 107 | 96 | 11 | % | 226 | 194 | 16 | % | |||||||||||||||
Enfamil | 209 | 196 | 7 | % | 59 | 56 | 5 | % | 150 | 140 | 7 | % | |||||||||||||||
Other Nutritional Products | |||||||||||||||||||||||||||
Toddler/Children's Nutritionals | 109 | 98 | 11 | % | 109 | 98 | 11 | % | — | — | — | ||||||||||||||||
Adult Consumer Nutritionals | 40 | 31 | 29 | % | 10 | 10 | — | 30 | 21 | 43 | % | ||||||||||||||||
OTHER HEALTHCARE | 434 | 405 | 7 | % | 195 | 168 | 16 | % | 239 | 237 | 1 | % | |||||||||||||||
CONVATEC PRODUCTS | 221 | 187 | 18 | % | 148 | 123 | 20 | % | 73 | 64 | 14 | % | |||||||||||||||
Ostomy | 133 | 114 | 17 | % | 89 | 78 | 14 | % | 44 | 36 | 22 | % | |||||||||||||||
Wound Care Products | 85 | 70 | 21 | % | 57 | 44 | 30 | % | 28 | 26 | 8 | % | |||||||||||||||
MEDICAL IMAGING | 130 | 118 | 10 | % | 23 | 17 | 35 | % | 107 | 101 | 6 | % | |||||||||||||||
Cardiolite | 83 | 75 | 11 | % | 11 | 7 | 57 | % | 72 | 68 | 6 | % | |||||||||||||||
CONSUMER MEDICINES | 83 | 100 | - -17 | % | 24 | 28 | - -14 | % | 59 | 72 | - -18 | % |
- *
- This table presents Total Company sales on a legal entity source basis and segment and product sales on a country management reported basis. As a result, the sum of segment sales for International and for Domestic do not tie to the Total Company International and Domestic sales shown above.
- **
- Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.
- ***
- In excess of 200%
7
BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE SALES BY PRODUCT
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2003
($ in millions)
| WORLDWIDE | INTERNATIONAL * | DOMESTIC * | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2003 | 2002 | % growth | 2003 | 2002 | % growth | 2003 | 2002 | % growth | ||||||||||||||||||
Total Company | $ | 15,100 | $ | 13,325 | 13 | % | $ | 5,799 | $ | 4,891 | 19 | % | $ | 9,301 | $ | 8,434 | 10 | % | |||||||||
PHARMACEUTICALS | 12,487 | 10,809 | 16 | % | 4,700 | 4,007 | 17 | % | 7,787 | 6,802 | 14 | % | |||||||||||||||
Cardiovasculars | 5,133 | 4,262 | 20 | % | 1,807 | 1,468 | 23 | % | 3,326 | 2,794 | 19 | % | |||||||||||||||
Pravachol/Pravigard Pac | 2,098 | 1,667 | 26 | % | 900 | 694 | 30 | % | 1,198 | 973 | 23 | % | |||||||||||||||
Plavix | 1,659 | 1,328 | 25 | % | 262 | 173 | 51 | % | 1,397 | 1,155 | 21 | % | |||||||||||||||
Avapro/ Avalide | 527 | 413 | 28 | % | 204 | 145 | 41 | % | 323 | 268 | 21 | % | |||||||||||||||
Monopril | 352 | 341 | 3 | % | 179 | 172 | 4 | % | 173 | 169 | 2 | % | |||||||||||||||
Coumadin | 249 | 238 | 5 | % | 18 | 19 | -5 | % | 231 | 219 | 5 | % | |||||||||||||||
Capoten/Captopril | 147 | 157 | -6 | % | 147 | 156 | -6 | % | — | 1 | -100 | % | |||||||||||||||
Anti-Cancer | 3,243 | 2,808 | 15 | % | 869 | 732 | 19 | % | 2,374 | 2,076 | 14 | % | |||||||||||||||
Oncology Therapeutics Network | 1,652 | 1,368 | 21 | % | — | — | — | 1,652 | 1,368 | 21 | % | ||||||||||||||||
Paraplatin | 701 | 576 | 22 | % | 95 | 83 | 14 | % | 606 | 493 | 23 | % | |||||||||||||||
TAXOL | 695 | 643 | 8 | % | 644 | 519 | 24 | % | 51 | 124 | -59 | % | |||||||||||||||
Anti-Infectives | 1,856 | 1,762 | 5 | % | 1,072 | 975 | 10 | % | 784 | 787 | — | ||||||||||||||||
Sustiva | 405 | 348 | 16 | % | 153 | 118 | 30 | % | 252 | 230 | 10 | % | |||||||||||||||
Zerit | 278 | 342 | -19 | % | 138 | 150 | -8 | % | 140 | 192 | -27 | % | |||||||||||||||
Cefzil | 210 | 182 | 15 | % | 65 | 55 | 18 | % | 145 | 127 | 14 | % | |||||||||||||||
Videx/ Videx EC | 199 | 198 | 1 | % | 117 | 103 | 14 | % | 82 | 95 | -14 | % | |||||||||||||||
Tequin | 143 | 140 | 2 | % | 28 | 18 | 56 | % | 115 | 122 | -6 | % | |||||||||||||||
Maxipime | 133 | 117 | 14 | % | 133 | 117 | 14 | % | — | — | — | ||||||||||||||||
Reyataz | 39 | — | — | 2 | — | — | 37 | — | — | ||||||||||||||||||
Central Nervous System | 254 | 349 | - -27 | % | 122 | 123 | - -1 | % | 132 | 226 | - -42 | % | |||||||||||||||
Serzone | 102 | 185 | -45 | % | 6 | 15 | -60 | % | 96 | 170 | -44 | % | |||||||||||||||
Sinemet | 74 | 75 | -1 | % | 61 | 57 | 7 | % | 13 | 18 | -28 | % | |||||||||||||||
BuSpar | 25 | 48 | -48 | % | 22 | 21 | 5 | % | 3 | 27 | -89 | % | |||||||||||||||
Other Pharmaceuticals | |||||||||||||||||||||||||||
Glucophage Franchise | 723 | 602 | 20 | % | 13 | 13 | — | 710 | 589 | 21 | % | ||||||||||||||||
Glucovance | 315 | 171 | 84 | % | 3 | 2 | 50 | % | 312 | 169 | 85 | % | |||||||||||||||
Glucophage XR | 306 | 248 | 23 | % | 1 | 1 | — | 305 | 247 | 23 | % | ||||||||||||||||
Glucophage | 99 | 183 | -46 | % | 8 | 10 | -20 | % | 91 | 173 | -47 | % | |||||||||||||||
Metaglip | 3 | — | — | 1 | — | — | 2 | — | — | ||||||||||||||||||
Abilify** | 203 | — | — | 2 | — | — | 201 | — | — | ||||||||||||||||||
NUTRITIONALS | 1,383 | 1,365 | 1 | % | 695 | 639 | 9 | % | 688 | 726 | - -5 | % | |||||||||||||||
Infant Formulas | 864 | 890 | - -3 | % | 317 | 294 | 8 | % | 547 | 596 | - -8 | % | |||||||||||||||
Enfamil | 520 | 571 | -9 | % | 174 | 171 | 2 | % | 346 | 400 | -14 | % | |||||||||||||||
Other Nutritional Products | |||||||||||||||||||||||||||
Toddler/Children's Nutritionals | 313 | 280 | 12 | % | 313 | 280 | 12 | % | — | — | — | ||||||||||||||||
Adult Consumer Nutritionals | 110 | 99 | 11 | % | 32 | 29 | 10 | % | 78 | 70 | 11 | % | |||||||||||||||
OTHER HEALTHCARE | 1,230 | 1,151 | 7 | % | 550 | 482 | 14 | % | 680 | 669 | 2 | % | |||||||||||||||
CONVATEC PRODUCTS | 602 | 539 | 12 | % | 406 | 347 | 17 | % | 196 | 192 | 2 | % | |||||||||||||||
Ostomy | 369 | 333 | 11 | % | 251 | 219 | 15 | % | 118 | 114 | 4 | % | |||||||||||||||
Wound Care Products | 225 | 199 | 13 | % | 150 | 125 | 20 | % | 75 | 74 | 1 | % | |||||||||||||||
MEDICAL IMAGING | 378 | 340 | 11 | % | 59 | 52 | 13 | % | 319 | 288 | 11 | % | |||||||||||||||
Cardiolite | 244 | 217 | 12 | % | 30 | 24 | 25 | % | 214 | 193 | 11 | % | |||||||||||||||
CONSUMER MEDICINES | 250 | 272 | - -8 | % | 85 | 83 | 2 | % | 165 | 189 | - -13 | % |
- *
- This table presents Total Company sales on a legal entity source basis and segment and product sales on a country management reported basis. As a result, the sum of segment sales for International and for Domestic do not tie to the Total Company International and Domestic sales shown above.
- **
- Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.
8
BRISTOL-MYERS SQUIBB COMPANY
EARNINGS BEFORE MINORITY INTEREST AND INCOME TAXES
EXCLUDING NON-COMPARABLE ITEMS
| 2002 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | TOTAL YEAR | ||||||||||||
Reported Earnings Before Minority Interest and Income Taxes | $ | 1,228 | $ | 724 | $ | 115 | $ | 580 | $ | 2,647 | |||||||
Non-comparable items: | |||||||||||||||||
Acquired in-process research and development | 160 | — | 7 | 2 | 169 | ||||||||||||
Provision for restructuring/other | 89 | 4 | 541 | 93 | 727 | ||||||||||||
Asset impairment charge | — | — | 379 | — | 379 | ||||||||||||
Gain on sale of businesses/product lines | (30 | ) | — | — | — | (30 | ) | ||||||||||
Tax issues | — | — | — | — | — | ||||||||||||
Earnings Before Minority Interest and Income Taxes excluding non-comparable items | $ | 1,447 | $ | 728 | $ | 1,042 | $ | 675 | $ | 3,892 | |||||||
| 2003 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | | TOTAL YEAR | |||||||||||
Reported Earnings Before Minority Interest and Income Taxes | $ | 1,075 | $ | 1,165 | $ | 1,292 | $ | 3,532 | ||||||||
Non-comparable items: | ||||||||||||||||
Provision for restructuring/other | 26 | (6 | ) | 55 | 75 | |||||||||||
Litigation settlement | (21 | ) | (41 | ) | (4 | ) | (66 | ) | ||||||||
Earnings Before Minority Interest and Income Taxes excluding non-comparable items | $ | 1,080 | $ | 1,118 | $ | 1,343 | $ | 3,541 | ||||||||
9
BRISTOL-MYERS SQUIBB COMPANY
DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS
EXCLUDING NON-COMPARABLE ITEMS
| 2002 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | TOTAL YEAR * | ||||||||||||
Reported Diluted EPS | $ | 0.43 | $ | 0.25 | $ | 0.17 | $ | 0.19 | $ | 1.05 | |||||||
Non-comparable items: | |||||||||||||||||
Acquired in-process research and development | 0.05 | — | — | — | 0.05 | ||||||||||||
Provision for restructuring/other | 0.03 | — | 0.17 | 0.03 | 0.22 | ||||||||||||
Asset impairment charge | — | — | 0.12 | — | 0.13 | ||||||||||||
Gain on sale of businesses/product lines | (0.01 | ) | — | — | — | (0.01 | ) | ||||||||||
Tax issues | — | — | (0.12 | ) | — | (0.12 | ) | ||||||||||
Diluted EPS excluding non-comparable items* | $ | 0.50 | $ | 0.25 | $ | 0.34 | $ | 0.24 | $ | 1.33 | |||||||
| 2003 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | | TOTAL YEAR * | |||||||||||
Reported Diluted EPS | $ | 0.39 | $ | 0.45 | $ | 0.45 | $ | 1.30 | ||||||||
Non-comparable items: | ||||||||||||||||
Provision for restructuring/other | 0.01 | — | 0.02 | 0.03 | ||||||||||||
Litigation settlement | (0.01 | ) | (0.01 | ) | — | (0.02 | ) | |||||||||
Diluted EPS excluding non-comparable items | $ | 0.39 | $ | 0.44 | $ | 0.47 | $ | 1.31 | ||||||||
- *
- — amounts may not add due to rounding of individual calculations.
10
BRISTOL-MYERS SQUIBB COMPANY
DEFERRED REVENUE IMPACT ON GROSS SALES
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2003
($ in millions)
| Q1 | Q2 | Q3 | September Year-to-Date | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glucophage | $ | 32.1 | $ | 25.0 | $ | 23.5 | $ | 80.6 | |||||
Paraplatin | 44.5 | — | — | 44.5 | |||||||||
Serzone | 17.2 | 17.5 | 7.3 | 42.0 | |||||||||
Plavix | 36.8 | — | — | 36.8 | |||||||||
Pravachol | 35.3 | — | — | 35.3 | |||||||||
Sustiva | 16.2 | 12.9 | — | 29.1 | |||||||||
Tequin | 15.1 | 11.0 | — | 26.1 | |||||||||
Cefzil | 22.0 | — | — | 22.0 | |||||||||
Monopril | 20.5 | — | — | 20.5 | |||||||||
Avapro | 17.2 | — | — | 17.2 | |||||||||
Videx | 7.6 | 4.2 | — | 11.8 | |||||||||
Glucophage XR | 11.3 | — | — | 11.3 | |||||||||
Glucovance | 11.0 | — | — | 11.0 | |||||||||
BuSpar | 5.4 | 2.7 | 0.4 | 8.5 | |||||||||
TAXOL | 7.4 | — | — | 7.4 | |||||||||
Zerit | 6.8 | — | — | 6.8 | |||||||||
Megace | — | 1.0 | 1.4 | 2.4 | |||||||||
306.4 | 74.3 | 32.6 | 413.3 | ||||||||||
Less: Deferred discounts | (10.9 | ) | (5.0 | ) | — | (15.9 | ) | ||||||
Total Impact on Gross Sales | $ | 295.5 | $ | 69.3 | $ | 32.6 | $ | 397.4 | * | ||||
- *
- amount is further reduced by approximately $86 of sales rebate and return accruals to arrive at an impact on net sales of $311.
11
BRISTOL-MYERS SQUIBB COMPANY
SELECT ADDITIONAL FINANCIAL INFORMATION
| ($ in Millions) | |||||
---|---|---|---|---|---|---|
Balance Sheet Items | September 30, 2003 | December 31, 2002 | ||||
Cash and cash equivalents | $ | 4,953 | $ | 3,978 | ||
Receivables, net of allowances | 3,588 | 2,968 | ||||
Short-term borrowings | 1,288 | 1,379 | ||||
Long-term debt | 7,421 | 6,261 | ||||
Stockholders' equity | $ | 10,065 | $ | 8,967 |
Other Items | ||||||
Quarterly Dividend (for the three months ended September 30, 2003): | $ | ..280/share | ||||
Gross Margin (for the three months ended September 30, 2003): | 64.2 | % | ||||
Capital Expenditures (for the three months ended September 30, 2003): | $ | 201 million |
12
BRISTOL-MYERS SQUIBB COMPANY SALES FOR THE PERIOD ENDED SEPTEMBER 30, 2003 ($ in millions)
BRISTOL-MYERS SQUIBB COMPANY SEGMENT SALES AND COMPOSITION OF CHANGE IN SALES FOR CONTINUING OPERATIONS FOR THE PERIOD ENDED SEPTEMBER 30, 2003 (DOLLARS IN MILLIONS)
BRISTOL-MYERS SQUIBB COMPANY 2003 THIRD QUARTER REVIEW ($ in Million)
BRISTOL-MYERS SQUIBB COMPANY 2003 NINE MONTH REVIEW ($ in Millions)
BRISTOL-MYERS SQUIBB COMPANY WORLDWIDE SALES BY PRODUCT FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2003 ($ in millions)
BRISTOL-MYERS SQUIBB COMPANY WORLDWIDE SALES BY PRODUCT FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2003 ($ in millions)
BRISTOL-MYERS SQUIBB COMPANY EARNINGS BEFORE MINORITY INTEREST AND INCOME TAXES EXCLUDING NON-COMPARABLE ITEMS
BRISTOL-MYERS SQUIBB COMPANY DEFERRED REVENUE IMPACT ON GROSS SALES FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2003 ($ in millions)
BRISTOL-MYERS SQUIBB COMPANY SELECT ADDITIONAL FINANCIAL INFORMATION